266 related articles for article (PubMed ID: 28062402)
1. The RAS-Effector Interaction as a Drug Target.
Keeton AB; Salter EA; Piazza GA
Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
[TBL] [Abstract][Full Text] [Related]
2. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
3. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
4. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic RAS: From Its Activation to Its Direct Targeting.
Zaravinos A
Crit Rev Oncog; 2017; 22(3-4):283-301. PubMed ID: 29604905
[TBL] [Abstract][Full Text] [Related]
6. Emerging strategies to target RAS signaling in human cancer therapy.
Chen K; Zhang Y; Qian L; Wang P
J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
[TBL] [Abstract][Full Text] [Related]
7. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
Counter C
Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
[TBL] [Abstract][Full Text] [Related]
8. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.
Waldmann H; Karaguni IM; Carpintero M; Gourzoulidou E; Herrmann C; Brockmann C; Oschkinat H; Müller O
Angew Chem Int Ed Engl; 2004 Jan; 43(4):454-8. PubMed ID: 14735533
[No Abstract] [Full Text] [Related]
9. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
11. The renewed battle against RAS-mutant cancers.
Zhang F; Cheong JK
Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
[TBL] [Abstract][Full Text] [Related]
12. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Teraishi F; Guo W; Zhang L; Dong F; Davis JJ; Sasazuki T; Shirasawa S; Liu J; Fang B
Cancer Res; 2006 Jun; 66(12):6072-9. PubMed ID: 16778179
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
14. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
15. Activated K-RAS and its effect on morphological appearance.
Kiyokawa E; Minato H
J Biochem; 2014 Sep; 156(3):137-45. PubMed ID: 24958732
[TBL] [Abstract][Full Text] [Related]
16. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
17. Blocking oncogenic Ras signaling for cancer therapy.
Adjei AA
J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
[TBL] [Abstract][Full Text] [Related]
18. Isoform-specific Ras signaling is growth factor dependent.
Hood FE; Klinger B; Newlaczyl AU; Sieber A; Dorel M; Oliver SP; Coulson JM; Blüthgen N; Prior IA
Mol Biol Cell; 2019 Apr; 30(9):1108-1117. PubMed ID: 30785867
[TBL] [Abstract][Full Text] [Related]
19. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
20. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
